Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer
Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy
Chang Gung Memorial Hospital
45 participants
Aug 1, 2022
INTERVENTIONAL
Conditions
Summary
A prospective cohort imaging study in a single institution to evaluate 68Ga- FAPI-46 and 18F-FDG PET/CT imaging for detecting recurrent tumor lesions in patients of ovarian cancer with CA125 elevation from complete response after therapy
Eligibility
Inclusion Criteria5
- Pathologically proven ovarian cancer with complete response after therapy
- Age between 30 and 80
- Elevation of serum CA125 value above the normal range (>35 U/mL) or doubling of serum CA125 value within the normal range
- ECOG performance status grade 0 or 1 and willing to receive further therapy if disease recurrence is confirmed
- Willing to enter this prospective study with signed informed consent form
Exclusion Criteria5
- Patients with history of other malignancy
- Patients who are pregnant or lactating
- Patients with fasting fingerstick glucose level higher than 200 mg/dl
- Known allergic reactions to components of the radiopharmaceutical solutions for intravenous injection for 68Ga-FAPI-46 or 18F-FDG imaging studies
- Patients who are incapable of lying still for 30 minutes to receive the PET/CT scan as assessed by investigators
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous injection of one dosage of 2 mCi 68Ga-FAPI-46
Intravenous injection of one dosage of 5-10mCi 18F-FDG
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06232122